Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PUMICE trial of rhPro-UK for acute mild ischemic stroke
ChiCTR2200062759Phase 3Not yet recruiting
- Sponsor
- Beijing Tiantan Hospital
- Start
- Aug 2022
- Modality
- Metabolic Enzymes → Therapeutic Enzymes → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of recombinant human prourokinase in ischemic stroke (2 arms), sponsored by Beijing Tiantan Hospital. Primary endpoint: Proportion of participants with mRS score 0 to 1 at 90 days. Planned start Aug 2022; status: not yet recruiting.
02
Drugs
recombinant human prourokinase
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on ChiCTR2200062759.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200062759.